高危WHO 2级弥漫性胶质瘤的治疗模式与结局:多中心回顾性队列研究
本研究为加拿大PROTECT多中心回顾性队列,纳入116例接受放疗联合辅助烷化剂化疗的高危WHO 2级弥漫性胶质瘤成人患者,中位随访71个月。结果显示生存结局良好,IDH状态是PFS唯一独立预测因素,TMZ与PCV在IDH突变患者中PFS无显著差异,但PCV毒性更高。
要点
- 高危WHO 2级胶质瘤放疗联合辅助烷化剂化疗结局良好,中位PFS 8.4年,5年OS率94.1%。
- IDH状态是PFS唯一独立预测因素(HR=3.54,95%CI 1.12-11.15;p=0.03)。
- IDH突变患者中TMZ与PCV的PFS无显著差异,但PCV剂量调整、治疗延迟及血液学毒性更高。
核心结论
- 高危WHO 2级弥漫性胶质瘤接受放疗联合辅助烷化剂化疗的结局良好,PCV较TMZ毒性更高,IDH突变状态是主要预后因素。
研究设计与样本
- PROTECT为加拿大多中心回顾性队列研究,纳入116例临床定义的高危WHO 2级弥漫性胶质瘤成人患者,接受放疗联合辅助烷化剂化疗。
主要发现
- 中位随访71个月,中位OS未达到,估计3年OS率97.3%、5年OS率94.1%。
- 中位PFS为8.4年,3年PFS率83.6%、5年PFS率77.9%。
- 可评估病例中IDH突变占84.6%,受检肿瘤中1p/19q共缺失占56.6%。
- 多因素分析中IDH状态是PFS唯一独立预测因素(HR=3.54,95%CI 1.12-11.15;p=0.03)。
- IDH突变患者中TMZ与PCV的PFS无显著差异,包括按1p/19q状态分层分析;PCV与更高的剂量调整、治疗延迟和血液学毒性相关。
临床怎么用
- 高危WHO 2级弥漫性胶质瘤术后放疗联合辅助烷化剂化疗可获良好生存,选择TMZ或PCV时需权衡PCV更高的毒性。
- IDH状态应作为预后分层和临床决策的重要依据。
局限性
- 回顾性多中心设计可能存在选择偏倚和信息偏倚。
- 部分分子标志物数据缺失(IDH状态可评估病例占84.6%,1p/19q仅受检肿瘤有结果)。
- 需前瞻性分子分层试验验证不同化疗方案的比较有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The optimal adjuvant alkylating chemotherapy regimen for high-risk WHO grade 2 glioma in the molecular era remains uncertain. We evaluated real-world treatment patterns, toxicity, and outcomes following radiotherapy with adjuvant temozolomide (TMZ) or procarbazine, lomustine, and vincristine (PCV) in a multicentre Canadian cohort. METHODS: PROTECT is a retrospective multicentre cohort study including adults with clinically defined high-risk WHO grade 2 diffuse glioma treated with radiotherapy and adjuvant alkylating chemotherapy. Clinical, molecular, treatment delivery, toxicity, surveillance, and survival data were collected. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared using the log-rank test and Cox regression. RESULTS: A total of 116 patients were included, with a median follow-up of 71 months. Isocitrate dehydrogenase (IDH) mutation was present in 84.6% of evaluable cases, and 1p/19q codeletion in 56.6% of tested tumours. Median OS was not reached, with estimated 3- and 5-year OS rates of 97.3% and 94.1%, respectively. Median PFS was 8.4 years, with 3- and 5-year PFS rates of 83.6% and 77.9%, respectively. In multivariable analysis, IDH status was the only independent predictor of PFS (HR = 3.54, 95% CI 1.12-11.15; p = 0.03). Among patients with IDH-mutant tumours, PFS did not differ significantly between TMZ and PCV, including in analyses stratified by 1p/19q status. PCV was associated with higher rates of dose modification, treatment delays, and hematologic toxicity. CONCLUSION: In high-risk WHO grade 2 glioma, outcomes were favorable with radiotherapy and adjuvant alkylating chemotherapies, with greater toxicity associated with PCV compared to TMZ. IDH mutational status emerged as the dominant prognostic factor. Prospective, molecularly stratified trials are necessary to characterize comparative effectiveness of regimens.
引用
- Jia JL, Alshamsan B, Andronic C, et al. Treatment patterns and outcomes in high-risk WHO grade 2 diffuse glioma: a multicentre retrospective cohort study. J Neurooncol. 2026. PMID: 42159820. doi:10.1007/s11060-026-05602-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。